Ken Griffin Ligand Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 10,800 shares of LGND stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,800

Previous 26,100 58.62%

Holding current value

$1.23 Million

Previous $2.2 Million 50.84%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$82.7 - $110.11 $1.82 Million - $2.42 Million	-21,996 Reduced 48.02%	23,814 $2.39 Million
Q2 2024 Aug 14, 2024	SELL	$68.53 - $87.91 $257,261 - $330,014	-3,754 Reduced 7.57%	45,810 $3.86 Million
Q1 2024 May 15, 2024	BUY	$68.64 - $89.2 $2.73 Million - $3.55 Million	39,762 Added 405.65%	49,564 $3.62 Million
Q4 2023 Feb 14, 2024	SELL	$49.57 - $72.63 $1.11 Million - $1.62 Million	-22,301 Reduced 69.47%	9,802 $700,000
Q3 2023 Nov 14, 2023	BUY	$58.86 - $72.67 $1.72 Million - $2.12 Million	29,241 Added 1021.7%	32,103 $1.92 Million
Q2 2023 Aug 14, 2023	SELL	$69.53 - $79.33 $4.87 Million - $5.55 Million	-69,995 Reduced 96.07%	2,862 $206,000
Q1 2023 May 15, 2023	SELL	$65.67 - $77.08 $5.26 Million - $6.17 Million	-80,071 Reduced 52.36%	72,857 $5.36 Million
Q4 2022 Feb 14, 2023	BUY	$61.72 - $96.74 $8.08 Million - $12.7 Million	130,960 Added 596.14%	152,928 $10.2 Million
Q3 2022 Nov 14, 2022	BUY	$0.01 - $107.56 $219 - $2.36 Million	21,968 New	21,968 $1.89 Million
Q1 2022 May 16, 2022	SELL	$94.99 - $151.56 $129,091 - $205,970	-1,359 Reduced 42.22%	1,860 $209,000
Q4 2021 Feb 14, 2022	SELL	$127.69 - $165.85 $1.33 Million - $1.72 Million	-10,382 Reduced 76.33%	3,219 $497,000
Q3 2021 Nov 15, 2021	BUY	$102.33 - $144.73 $649,079 - $918,022	6,343 Added 87.39%	13,601 $1.89 Million
Q2 2021 Aug 16, 2021	SELL	$113.03 - $155.64 $176,665 - $243,265	-1,563 Reduced 17.72%	7,258 $952,000
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $8.88 Million - $19.2 Million	-89,190 Reduced 91.0%	8,821 $1.34 Million
Q4 2020 Feb 16, 2021	SELL	$80.55 - $106.05 $10.4 Million - $13.6 Million	-128,527 Reduced 56.74%	98,011 $9.75 Million
Q3 2020 Nov 16, 2020	BUY	$89.56 - $126.72 $12.8 Million - $18.1 Million	142,561 Added 169.76%	226,538 $21.6 Million
Q2 2020 Aug 14, 2020	SELL	$68.28 - $123.65 $7.23 Million - $13.1 Million	-105,853 Reduced 55.76%	83,977 $9.39 Million
Q1 2020 May 15, 2020	BUY	$63.37 - $107.88 $4.23 Million - $7.2 Million	66,741 Added 54.22%	189,830 $13.8 Million
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $36,352 - $42,596	-375 Reduced 0.3%	123,089 $12.8 Million
Q3 2019 Nov 14, 2019	BUY	$86.25 - $120.16 $4.26 Million - $5.93 Million	49,354 Added 66.6%	123,464 $12.3 Million
Q2 2019 Aug 14, 2019	SELL	$107.38 - $129.34 $3.44 Million - $4.14 Million	-32,039 Reduced 30.18%	74,110 $8.46 Million
Q1 2019 May 15, 2019	BUY	$105.93 - $142.47 $5.24 Million - $7.05 Million	49,457 Added 87.24%	106,149 $0
Q4 2018 Feb 14, 2019	BUY	$128.36 - $272.13 $6.95 Million - $14.7 Million	54,121 Added 2105.06%	56,692 $7.69 Million
Q3 2018 Nov 13, 2018	SELL	$211.18 - $274.49 $1.89 Million - $2.46 Million	-8,949 Reduced 77.68%	2,571 $0
Q2 2018 Aug 10, 2018	BUY	$150.77 - $207.98 $1.52 Million - $2.1 Million	10,106 Added 714.71%	11,520 $0
Q1 2018 May 11, 2018	SELL	$138.63 - $182.62 $142,511 - $187,733	-1,028 Reduced 42.1%	1,414 $234,000
Q4 2017 Feb 09, 2018	SELL	$128.36 - $147.04 $172,002 - $197,033	-1,340 Reduced 35.43%	2,442 $334,000
Q3 2017 Nov 09, 2017	BUY	$120.91 - $137.94 $457,281 - $521,689	3,782	3,782 $515,000

Others Institutions Holding LGND

# of Institutions

256

Shares Held

18.1M

Call Options Held

26.8K

Put Options Held

9.3K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.92B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account